Nephroureterectomy vs. segmental ureterectomy of clinically localized, high-grade, urothelial carcinoma of the ureter: Practice patterns and outcomes

医学 泌尿科 尿路上皮癌 肾盂 解剖(医学) 阶段(地层学) 输尿管 比例危险模型 队列 T级 淋巴结 肾切除术 单变量分析 逻辑回归 多元分析 内科学 癌症 肿瘤科 外科 膀胱癌 肾 生物 古生物学
作者
Javier Piraino,Zachary A. Snow,Daniel C. Edwards,Shaun Hager,Brian McGreen,Gregory Diorio
出处
期刊:Urologic Oncology-seminars and Original Investigations [Elsevier BV]
卷期号:38 (11): 851.e1-851.e10 被引量:13
标识
DOI:10.1016/j.urolonc.2020.08.004
摘要

Nephroureterectomy (NU) remains the gold-standard for upper-tract urothelial carcinoma (UTUC). However, nephron-sparing management (NSM), specifically segmental ureterectomy (SU) for urothelial tumors distal to the renal pelvis may offer decreased risk of renal insufficiency and equivalent cancer control. To identify patient-specific and facility-related factors that are associated with the selection of SU vs. NU for patients with clinically localized, high-grade, ureteral UTUC. We searched the National Cancer Database between 2004 and 2015 for patients with high-grade, clinically localized, primary ureteral UTUC managed by either NU or SU. Univariate and multivariate analysis was performed to assess patient, disease-specific, facility and treatment-related factors associated with SU vs. NU. Since surgical approach was only indexed after 2010, separate multivariable logistic regressions were performed including and excluding surgical approach in order to capture patients treated between 2004 and 2009. Survival analysis utilized Kaplan-Meier methods and Cox proportional hazards regression. Multivariate analysis including surgical approach demonstrated that among other factors, higher clinical stage (P = 0.034), larger tumor size (P < 0.001), the addition of neoadjuvant chemotherapy (P = 0.002), and the utilization of minimally invasive surgery (P < 0.05) decreased the likelihood of patients receiving SU. In this same cohort, institutions with larger facility volumes (P = 0.038) and performing intraoperative lymph node dissection (P < 0.001) were associated with a higher probability of SU. Excluding surgical approach, once again more advanced clinical stage (P = 0.005), larger tumor size (P < 0.001), and neoadjuvant chemotherapy (P = 0.003) decreased the probability of patients receiving SU, while increasing age (P = 0.049) and intraoperative lymph node dissection (P < 0.001) were more closely associated with SU compared to NU. No differences were noted in pathological T stage (P > 0.05), 30-day readmission (P = 0.7), 30-day mortality (P = 0.09), and 90-day mortality (P = 0.157) on multivariate analysis between SU and NU. Additionally, no significant differences were seen in median overall survival between patients receiving SU or NU (53 vs. 50 months; P = 0.143). Comparable outcomes suggest segmental ureterectomy for high-grade ureteral UTUC is appropriate in well-selected patients. Practice patterns appear consistent with guideline recommendations (decreased tumor size and lower clinical stage favor SU), but treatment disparities may exist based on a multitude of patient, pathologic- and facility-related factors. Improved dissemination of knowledge regarding practice patterns and outcomes of SU for UTUC of the ureter has the potential to improve delivery of NSM in appropriate patients. In this study, we examined factors associated with different surgical procedures for cancer of the ureter. We found that smaller tumor sizes, a less advanced clinical stage, intraoperative lymph dissection higher facility volumes tended to favor kidney-sparing treatment, while survival outcomes appear comparable to renal extirpation.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
乐乐的应助被科研通管家采纳,获得10
刚刚
刚刚
orixero的应助被科研通管家采纳,获得10
刚刚
乐乐的应助被科研通管家采纳,获得10
刚刚
领导范儿的应助被GS采纳,获得10
刚刚
FashionBoy的应助被科研通管家采纳,获得10
刚刚
Julo发布了新的文献求助10
刚刚
刚刚
极限001的应助被科研通管家采纳,获得30
1秒前
丘比特的应助被科研通管家采纳,获得10
1秒前
orixero的应助被科研通管家采纳,获得10
1秒前
华仔的应助被科研通管家采纳,获得10
1秒前
英俊的铭的应助被科研通管家采纳,获得10
1秒前
Akim的应助被科研通管家采纳,获得30
1秒前
斯文败类的应助被科研通管家采纳,获得10
1秒前
隐形曼青的应助被科研通管家采纳,获得10
1秒前
烟花的应助被科研通管家采纳,获得10
2秒前
今后的应助被科研通管家采纳,获得30
2秒前
Lucas的应助被科研通管家采纳,获得10
2秒前
wu完成签到 ,获得积分10
2秒前
2秒前
研友_VZG7GZ的应助被科研通管家采纳,获得10
2秒前
2秒前
2秒前
xxcub发布了新的文献求助10
2秒前
Ava的应助被科研通管家采纳,获得10
2秒前
2秒前
阿毛0226完成签到,获得积分10
3秒前
桐桐的应助被畅快的凡灵采纳,获得30
4秒前
qian发布了新的文献求助10
4秒前
5秒前
5秒前
科研通AI6.4的应助被luyiyi采纳,获得10
5秒前
5秒前
sufu_jony的应助被luyiyi采纳,获得10
5秒前
彭于晏的应助被2021采纳,获得10
6秒前
Djk520222发布了新的文献求助10
7秒前
sufu_jony的应助被不老实采纳,获得10
7秒前
xhj666完成签到,获得积分10
7秒前
wzbc完成签到,获得积分10
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8171477
求助须知:如何正确求助?哪些是违规求助? 9564248
关于积分的说明 21774106
捐赠科研通 7763073
什么是DOI,文献DOI怎么找? 3430972
关于科研通互助平台的介绍 2554805
邀请新用户注册赠送积分活动 2475887